Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML0325

Sigma-Aldrich

Retigabine

≥98% (HPLC)

Sinonimo/i:

D-23129, Ezogabine, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C16H18FN3O2
Numero CAS:
150812-12-7
Peso molecolare:
303.33
Beilstein:
8072099
Numero MDL:
MFCD04307735
Codice UNSPSC:
12352200
ID PubChem:
329825330
NACRES:
NA.77
Prezzi e disponibilità al momento non sono disponibili

Saggio

≥98% (HPLC)

Stato

powder

Controllo stupefacenti

USDEA Schedule V

Colore

white to light brown

Solubilità

DMSO: >15 mg/mL

Temperatura di conservazione

room temp

Stringa SMILE

FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1

InChI

1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
PCOBBVZJEWWZFR-UHFFFAOYSA-N

Informazioni sul gene

human ... KCNQ1(3784) , KCNQ2(3785) , KCNQ3(3786) , KCNQ4(9132) , KCNQ5(56479)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Retigabine (Ezogabine) is a Kv7.2-7.5 (KCNQ2-5) neuronal potassium channel opener witrh anticonvulsant activity.
Retigabine is a Kv7.2-7.5 potassium channel activator; anticonvulsant.

Pittogrammi

Skull and crossbonesEnvironment
GHS06,GHS09

Avvertenze

Danger

Indicazioni di pericolo

H301 + H331,H410

Classi di pericolo

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000240539
0000240539
0000180398
086M4611V
042M4736V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Diazoxide

Sigma-Aldrich

D9035

Diazoxide

Icilin ≥97% (HPLC), solid

Sigma-Aldrich

I9532

Icilin

Carbamazepine powder

Sigma-Aldrich

C4024

Carbamazepine

Lamotrigine ≥98%, powder

Sigma-Aldrich

L3791

Lamotrigine

Acetaminofene meets USP testing specifications, 98.0-102.0%, powder

Sigma-Aldrich

A5000

Acetaminofene

Dimetil solfossido Hybri-Max™, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%

Sigma-Aldrich

D2650

Dimetil solfossido

Martin J Gunthorpe et al.
Epilepsia, 53(3), 412-424 (2012-01-10)
The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2-7.5) ion channels
Roger J Porter et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 149-154 (2007-01-03)
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase
Gökce Orhan et al.
Expert opinion on pharmacotherapy, 13(12), 1807-1816 (2012-07-13)
Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a
Michele A Faulkner et al.
Expert opinion on drug safety, 12(6), 847-855 (2013-07-26)
Complex-partial seizures are frequently resistant to antiepileptic therapy. Two new medications with mechanisms of action novel within the antiepileptic class have recently received approval for the adjunctive treatment of partial (focal) seizures. A Medline search was conducted to identify preclinical
Philip N Patsalos et al.
Expert opinion on pharmacotherapy, 13(5), 699-715 (2012-03-13)
The search for new, more effective antiepileptic drugs (AEDs) continues. The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults. For the above
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.